IRLAB Therapeutics AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	92.46	57.46	94.63	5.68	61.14	207.78
Other Revenue	-2.55	-	-	-	-	-
Revenue	89.91	57.46	94.63	5.68	61.14	207.78
Revenue Growth (YoY)	-12.44%	-39.28%	1566.57%	-90.71%	-70.58%	69160.67%
Cost of Revenue	96.91	99.38	136.29	128.41	125.91	81.74
Gross Profit	-7	-41.91	-41.66	-122.73	-64.77	126.05
Selling, General & Admin	44.46	46.12	46.18	53.08	42.48	31.02
Other Operating Expenses	-1.67	1.05	-19.46	-0.04	-0.03	38.97
Operating Expenses	47.03	51.48	31.31	57.36	47.23	73.47
Operating Income	-54.03	-93.4	-72.97	-180.09	-112	52.58
Interest Expense	-14.36	-17.99	-10.48	-0.2	-0.3	-0.37
Interest & Investment Income	1.47	1.38	2.46	3.13	-	0
Currency Exchange Gain (Loss)	-	-	-2.14	-0.68	-1.11	-0.43
Other Non Operating Income (Expenses)	-	-0	-	0	-	-
EBT Excluding Unusual Items	-66.92	-110.01	-83.13	-177.84	-113.41	51.78
Pretax Income	-66.92	-110.01	-83.13	-177.84	-113.41	51.78
Earnings From Continuing Operations	-66.92	-110.01	-83.13	-177.84	-113.41	51.78
Net Income	-66.92	-110.01	-83.13	-177.84	-113.41	51.78
Net Income to Common	-66.92	-110.01	-83.13	-177.84	-113.41	51.78
Shares Outstanding (Basic)	75	67	52	52	52	52
Shares Outstanding (Diluted)	75	67	52	52	52	52
Shares Change (YoY)	43.64%	29.17%	-	0.07%	0.16%	8.54%
EPS (Basic)	-0.90	-1.64	-1.60	-3.43	-2.19	1.00
EPS (Diluted)	-0.90	-1.64	-1.60	-3.43	-2.19	1.00
Free Cash Flow	-96.2	-55.22	-65.79	-165.14	-145.49	127.93
Free Cash Flow Per Share	-1.29	-0.82	-1.27	-3.18	-2.81	2.47
Gross Margin	-7.78%	-72.94%	-44.03%	-	-105.94%	60.66%
Operating Margin	-60.09%	-162.54%	-77.11%	-3171.72%	-183.20%	25.30%
Profit Margin	-74.43%	-191.45%	-87.85%	-3132.07%	-185.50%	24.92%
Free Cash Flow Margin	-106.99%	-96.10%	-69.52%	-2908.47%	-237.97%	61.57%
EBITDA	-49.75	-89.08	-72.08	-179.17	-111.27	53.07
EBITDA Margin	-55.34%	-155.02%	-76.17%	-	-182.00%	25.54%
D&A For EBITDA	4.28	4.32	0.89	0.92	0.74	0.49
EBIT	-54.03	-93.4	-72.97	-180.09	-112	52.58
EBIT Margin	-60.09%	-162.54%	-77.11%	-	-183.20%	25.30%
Revenue as Reported	95.24	62.8	114.08	5.72	61.28	207.91

Source: S&P Global Market Intelligence. Standard template. Financial Sources.